Pompano Beach, Fl., April 15, 2021 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a pre-clinical-stage biotechnology company focused on harnessing elements of perinatal tissue for use in regenerative therapies, today announced the launch of a national sales force expansion. The expansion aims to increase the number of dedicated regional sales representatives actively selling the Company’s perinatal tissue allografts.
As the economy reopens from blanket shutdowns related to COVID-19 prevention, treatment facilities are resuming elective surgeries and regenerative therapies. The Company plans to capitalize on the growing demand for high quality perinatal tissue allografts, precipitated by the booming return of these medical procedures.
BioStem will be hiring experienced sales representatives with technical knowledge and business competencies in the orthopedic, wound care and urology verticals.
The regional focus of the expansion will concentrate on three regions, North East (with states such as New York, Pennsylvania, Connecticut, and New Jersey), Midwest (with states such as Illinois, Ohio, Minnesota and Wisconsin) and the Mountain Region (with states such as Nevada, Arizona, Colorado, Utah, New Mexico, Montana and Wyoming).
Qualified sales representatives who may be interested are asked to visit www.biostemtechnologies.com/agents and fill out the contact form to receive more information.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a pre-clinical-stage biotechnology company focused on harnessing elements of Perinatal Tissue and the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Our proprietary approach, called Local Microenvironment Activation, or LMA, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. BioStem Technologies offers a comprehensive portfolio of high-quality brands that include RHEO™, OROPRO™, AEON™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.